Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2

NCT04973449 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04973449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04973449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2
Lead sponsor
AstraZeneca
Phase
Phase 2/3
Overall status
Completed
Start date
June 27, 2021
Completion date
August 2, 2022
Enrollment
2,843 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2